Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Bernhard Hebich"'
Autor:
Hayat Bähr-Mahmud, Ursula Ellinghaus, Christiane R. Stadler, Leyla Fischer, Claudia Lindemann, Anuhar Chaturvedi, Jan Diekmann, Stefan Wöll, Imke Biermann, Bernhard Hebich, Caroline Scharf, Manuela Siefke, Alexandra S. Roth, Martin Rao, Kerstin Brettschneider, Eva-Maria Ewen, Uğur Şahin, Özlem Türeci
Publikováno v:
OncoImmunology, Vol 12, Iss 1 (2023)
ABSTRACTIMAB362/Zolbetuximab, a first-in-class IgG1 antibody directed against the cancer-associated gastric-lineage marker CLDN18.2, has recently been reported to have met its primary endpoint in two phase 3 trials as a first-line treatment in combin
Externí odkaz:
https://doaj.org/article/9d221a17a4384e5ba41b5f63a1b80c51
Autor:
Christiane R Stadler, Hayat Bähr-Mahmud, Leyla Celik, Bernhard Hebich, Alexandra S Roth, René P Roth, Katalin Karikó, Özlem Türeci, Ugur Sahin
Publikováno v:
Nature medicine. 23(10)
This corrects the article DOI: 10.1038/nm.4356.
Autor:
Alexandra S Roth, Katalin Karikó, Özlem Türeci, Bernhard Hebich, René P Roth, Ugur Sahin, Leyla Celik, Christiane Stadler, Hayat Bähr-Mahmud
Publikováno v:
Nature medicine. 23(7)
The potential of bispecific T cell-engaging antibodies is hindered by manufacturing challenges and short serum half-life. We circumvented these limitations by treating mice with in vitro-transcribed pharmacologically optimized, nucleoside-modified mR
Publikováno v:
Gastroenterology. 142:S-1024
Publikováno v:
Gastroenterology. 142:S-269
Publikováno v:
Gastroenterology. 142:S-974